Helping people in subsidized housing create smoke-free homes
A smoke-free home intervention in federally subsidized housing
This study is all about helping people from different backgrounds who live in subsidized housing to quit smoking and create smoke-free homes, especially focusing on those who might need extra support, like Black, Hispanic, and Asian individuals who speak limited English.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11036321 on NIH RePORTER |
What this research studies
This research focuses on reducing tobacco use and exposure among racially and ethnically diverse populations living in federally subsidized housing. It aims to increase access to smoke-free homes and cessation resources, particularly for Black/African American, Hispanic/Latino, and Asian individuals with limited English proficiency. The study will implement and promote smoke-free policies and voluntary adoption of smoke-free homes, building on previous pilot work to assess effectiveness and feasibility. Participants will receive support and resources to help them transition to smoke-free living environments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living in federally subsidized housing, particularly from racially and ethnically diverse backgrounds.
Not a fit: Patients who do not reside in federally subsidized housing or who do not use tobacco may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to healthier living conditions and reduced tobacco-related health disparities for residents in subsidized housing.
How similar studies have performed: Previous research has shown that smoke-free policies can effectively reduce tobacco use and exposure, indicating a promising approach for this intervention.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Vijayaraghavan, Maya — University of California, San Francisco
- Study coordinator: Vijayaraghavan, Maya
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.